Sham Research and Ghostwriting: When Pharma Research Payments Buy Prescriptions

Pharmaceutical research kickbacks and ghostwriting can put a research label on payments for prescriptions or a doctor’s name on work the company supplied. If you work in medical writing, clinical research or grant administration, the revealing detail may be who wrote the article, what the doctor delivered, or why payment depended on using the drug. The contract calls it research. The people running it may be measuring sales.

What Is a Pharmaceutical Kickback?

A pharmaceutical kickback is money or another benefit offered to induce or reward prescribing or other business paid for by a federal health care program. Research grants, authorship payments and data-purchase agreements can carry that incentive. The connection runs from the manufacturer’s payment to the doctor’s decision and then to the prescription or procedure the government pays for.

In its 2003 guidance for pharmaceutical manufacturers, the Department of Health and Human Services’ Office of Inspector General warned that postmarketing research could serve as a pretext to generate prescriptions.

That makes the origin of a project revealing. The guidance singles out research contracts originating in sales or marketing, and research offered to purchasers during sales contacts. An employee who knows how a grant reached the research department may know more about its purpose than the final contract says.

The idea was already recognizable in a fraud alert from the Inspector General in 1994. It described doctors receiving substantial payments for administering a manufacturer’s drug and making brief treatment notes, sometimes only a single word. The paperwork was slight. The payment followed the use of the product.

Ghostwriting Gives the Sales Message a Doctor’s Name

Medical ghostwriting can let a manufacturer supply the article while a recruited doctor supplies the authorship. In AstraZeneca’s Seroquel case, the government alleged that medical literature companies ghostwrote articles about studies the named doctors had not conducted. The government said AstraZeneca then used the studies and articles to promote unapproved uses of Seroquel.

The Justice Department’s April 2010 announcement also described alleged illegal payments to doctors recruited as authors of articles written by AstraZeneca and its agents. In the alleged arrangement, a doctor appeared on the article, the company supplied the work, and the company used the result in promotion.

AstraZeneca agreed to a $520 million civil settlement covering the broader Seroquel promotion and physician-payment allegations.

The literature review Corporate crime in the pharmaceutical industry is common, serious and repetitive, published in shorter form in the BMJ in 2012, described a similar connection in the marketing of Neurontin. The review reported that Warner-Lambert tracked high-volume prescribers and rewarded them through speaking, consulting or patient recruitment for studies. It also described paying doctors to lend their names to ghostwritten articles promoting unapproved uses.

An article’s influence can also reach the drug reference books used in government coverage decisions. In a separate Amgen case, the government alleged that the company used inadequate journal articles to obtain listings in medical compendia, seeking coverage for unapproved uses. A whistleblower’s complaint alleged that ghostwritten Aranesp articles and tainted studies helped secure those listings. The publication could reach the government’s payment decision as well as the prescriber’s desk.

For a medical writer, the comparison is concrete: the assignment, the drafts, the named author’s contribution and the eventual use of the article. We examine that sequence with you, including who commissioned the work and who approved its promotional use. An authorship line can conceal the very relationship those records reveal.

Galena’s RELIEF Registry Allegedly Paid for Patient Referrals

Galena Biopharma’s RELIEF patient registry allegedly used payments for patient referrals to induce doctors to prescribe Abstral. The registry was presented as a way to collect information about patients’ experiences with the drug. According to the government, it also served as a prescribing incentive.

The September 2017 civil settlement announcement covered more than $7.55 million for a broader set of alleged Abstral kickbacks.

The registry question is what the payment bought. We connect the promised patient-experience data to the referral arrangement and the prescribing decisions behind it. The employee handling enrollment or payments may see that connection in a way the registry’s stated purpose never explains.

Amgen’s Deep Dive Survey Allegedly Became a Payment for Prescribing

A drug company physician survey limited to prescribers of its own product was central to the government’s Deep Dive allegations against Amgen. The alleged change was specific: Amgen increased the payment and made it available only to doctors who prescribed Xgeva.

The Justice Department’s account describes an original plan to pay doctors for a short online survey about how they treated patients with bone cancer, including which drugs they used. Payment under that plan did not depend on prescribing Xgeva. The government alleged that Amgen changed that condition to encourage use of its drug.

The marketing team’s access mattered too. It was not supposed to know which doctors received Deep Dive contracts, but the government said team members could access their identities. The alleged arrangement combined a prescribing condition with information about the doctors receiving the money.

Amgen paid the United States more than $15 million in July 2013 to settle allegations involving Deep Dive and other financial incentives for Xgeva prescribing. Two employees brought the whistleblower case, and the government took over part of it. The employees were to receive a combined $2.75 million from the settlement.

For someone who saw the project change, the earlier version matters. The alleged shift was from paying for an answer to paying only a prescriber of Amgen’s drug.

Pacira Allegedly Wanted Formulary Placement Before Research

Pacira Pharmaceuticals allegedly required Exparel to be placed on a physician’s hospital formulary before it would award a research grant. Sales representatives or marketing executives typically initiated the grants and discussed their sales goals internally. The July 2020 settlement announcement set the civil settlement at $3.5 million.

Formulary placement puts a product on an institution’s approved drug list. In the alleged arrangement, access to the hospital came before the research money. After awarding a grant, the government said, Pacira showed little interest in whether the research happened.

The government alleged that Pacira did not require research milestones before payment and, in some cases, recipients performed no work at all. It also alleged that executives coached recipients and employees on avoiding internal scrutiny.

The pharmacist who brought the case described a research offer in the complaint:

That allegation places the offer inside a sales contact. The government’s later account connects the grants to hospital purchasing and to Exparel used in procedures reimbursed by Medicare and Medicaid. The hospital got access to grant money, the manufacturer sought product sales, and taxpayers paid for the resulting care.

Manufacturer-Controlled CME Topics, Speakers and Brand Materials

When a manufacturer controls CME speaker topics and brand materials, its commercial influence reaches continuing medical education. In the government’s Protonix allegations, Wyeth funded education through grants that promised it would not influence the content, while its brand team allegedly shaped topics, speaker selection, organization and content.

The Justice Department’s December 2012 account described an especially revealing detail: Wyeth allegedly insisted that the educational materials use the same colors and appearance as Protonix promotional materials. They had a name for it: branducation.

For someone working with an education vendor, the funding agreement and the brand team’s instructions can tell different stories about who controls the program. Here the promised independence and the alleged instructions collided down to the appearance of the materials. That is the connection to ghostwriting: the company can shape a message that reaches doctors through someone else’s apparent authority.

What Evidence Is Needed to Prove Fraud?

Evidence of sham research connects the stated project, the work actually performed, the payment and the prescribing or purchasing decision. The useful records show who selected the doctors, what they were asked to do, what triggered payment and how the manufacturer used the result.

We examine the protocol and grant proposal alongside the commercial discussions that produced them. Pacira’s alleged sales goals and formulary condition explain why the grant was offered. Amgen’s original and revised survey terms explain who became eligible to be paid. In AstraZeneca’s alleged authorship arrangement, the manuscript work and the named doctor’s actual contribution are the comparison.

The underlying business has several decision-makers. Formulary rules can shape access to a drug, doctors prescribe it, and providers or pharmacies submit the government-payment claims. A manufacturer can influence those decisions through a payment made well before the claim. That is why we connect the grant or writing arrangement to the healthcare business it was intended to generate.

A publication or clinical-research employee may hold the scientific side of that connection. A sales employee may know why a particular doctor was selected. Finance may know which condition released the payment. We work across those perspectives to build the account of what the company bought and who understood the arrangement.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

Open Payments Shows the Transfer, While the Contract Shows Its Purpose

Open Payments reports transfers of value, but it does not contain the prescribing data needed to connect a payment to a prescription. The entry shows the reported transfer. The proposal, delivered work and payment terms help explain what it bought.

The Inspector General’s guidance also addresses the limits of disclosure: revealing sponsorship or a financial relationship can reduce the risk of abuse, but disclosure does not eliminate that risk. In the cases above, the revealing details were conditions such as prescribing a named drug or securing formulary placement, and the mismatch between promised research and work performed. We examine those details with you, including the decisions behind the disclosed payment.

When You Know What the Research Payment Bought

If you know why the grant depended on a prescription or how a doctor’s name reached an article the company wrote, speak to one of our whistleblower experts about what the research payment bought. We work with you to connect the research, payments and government claims into your strongest pharmaceutical whistleblower case, and bring in pharmaceutical fraud whistleblower lawyers who understand research-payment schemes. We stay beside you from that first account through the case.